Recent advances in the treatment and outcome of locally advanced rectal cancer

被引:46
|
作者
Vauthey, JN
Marsh, RD
Zlotecki, RA
Abdalla, EK
Solorzano, CC
Bray, EJ
Freeman, ME
Lauwers, GY
Kubilis, PS
Mendenhall, WM
Copeland, EM
机构
[1] Univ Florida, Coll Med, Dept Surg, Gainesville, FL USA
[2] Univ Florida, Coll Med, Dept Med, Div Hematol Oncol, Gainesville, FL USA
[3] Univ Florida, Coll Med, Dept Radiat Therapy, Gainesville, FL USA
[4] Univ Florida, Coll Med, Dept Pathol, Gainesville, FL USA
[5] Univ Florida, Coll Liberal Arts & Sci, Dept Stat, Div Biostat, Gainesville, FL USA
关键词
D O I
10.1097/00000658-199905000-00018
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective To compare the outcomes of treatment of locally advanced rectal cancer of the early era (1975-1990) with those of the late era (1991-1997). Background Preoperative therapy has been used in locally advanced rectal cancer to preserve sphincter function, decrease local recurrence, and improve survival. At the University of Florida, preoperative radiation has been used since 1975, and it was combined with chemotherapy beginning in 1991. Methods The records of 328 patients who underwent preoperative radiation or chemoradiation followed by complete resection for locally advanced rectal cancer defined as tethered, annular, or fixed tumors were reviewed. The clinicopathologic characteristics, adjuvant treatment administered, surgical procedures performed, and local recurrence-free and overall survival rates were analyzed. Results There were 219 patients in the early era and 109 in the late era. No significant differences were seen in patients (age, gender, race) or tumor characteristics (mean distance from the anal verge, annularity, fixation). Preoperative radiation regimens were radiobiologically comparable. No patient in the early era received preoperative chemotherapy, compared with 64 in the late era. Of those receiving any pre- or postoperative chemotherapy, three patients received chemotherapy in the early era, compared with 76 in the late era. Sphincter-preserving procedures increased from 13% in the early era to 52% in the late era. Pathologic downstaging for depth of invasion increased from 42% to 58%, but lymph node negativity remained similar. The 1-, 3-, and 5-year local recurrence-free survival rates were comparable. However, in the late era, 1-, 3-, and 5-year overall survival rates improved significantly compared with those of the early era, and also compared with each of the preceding 5-year intervals. Conclusion The addition of a chemotherapy regimen to preoperative radiation therapy improves survival over radiation therapy alone. Likewise, an improvement in downstaging is associated with an increase iii sphincter-preserving procedures.
引用
收藏
页码:745 / 754
页数:10
相关论文
共 50 条
  • [41] Techniques and Outcome of Surgery for Locally Advanced and Local Recurrent Rectal Cancer
    Renehan, A. G.
    [J]. CLINICAL ONCOLOGY, 2016, 28 (02) : 103 - 115
  • [42] Outcome of abdominosacral resection for locally advanced primary and recurrent rectal cancer
    Bhangu, A.
    Brown, G.
    Akmal, M.
    Tekkis, P.
    [J]. BRITISH JOURNAL OF SURGERY, 2012, 99 (10) : 1453 - 1461
  • [43] The Role of Intraoperative Radiotherapy Treatment of Locally Advanced Rectal Cancer
    Amarnath, Sudha R.
    [J]. CLINICS IN COLON AND RECTAL SURGERY, 2024, 37 (04) : 239 - 247
  • [44] Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients
    Francesca De Felice
    Daniele Crocetti
    Veronica Maiuri
    Martina Parisi
    Francesco Marampon
    Luciano Izzo
    Giorgio De Toma
    Daniela Musio
    Vincenzo Tombolini
    [J]. Current Treatment Options in Oncology, 2020, 21
  • [45] Use of Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer
    Hu, Katherine Y.
    Simpson, Matthew T.
    Blank, Jacqueline J.
    Szabo, Aniko
    Eastwood, Daniel
    Ludwig, Kirk A.
    Peterson, Carrie Y.
    Ridolfi, Timothy J.
    [J]. JOURNAL OF SURGICAL RESEARCH, 2019, 243 : 447 - 452
  • [46] Neoadjuvant treatment for locally advanced rectal cancer: a systematic review
    Keisuke Uehara
    Masato Nagino
    [J]. Surgery Today, 2016, 46 : 161 - 168
  • [47] Treatment of locally advanced and recurrent rectal cancer in Australia and New Zealand: recent progress and future challenges
    Brown, Kilian G. M.
    Solomon, Michael J.
    Heriot, Alexander
    Frizelle, Frank
    [J]. ANZ JOURNAL OF SURGERY, 2023, 93 (10) : 2291 - 2292
  • [48] Inclusion of Oxaliplatin in the multimodal Treatment of locally advanced Rectal Cancer
    Roedel, Claus
    Fokas, Emmanouil
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (02) : 168 - 170
  • [49] Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer
    Sullo, Francesco Giulio
    Passardi, Alessandro
    Gallio, Chiara
    Molinari, Chiara
    Marisi, Giorgia
    Pozzi, Eleonora
    Solaini, Leonardo
    Bittoni, Alessandro
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
  • [50] ctDNA responds to neoadjuvant treatment in locally advanced rectal cancer
    Buertin, Florian
    Elias, Liema
    Hinz, Sebastian
    Forster, Michael
    Hildebrandt, Guido
    Frerker, Bernd
    Bock, Felix
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (09)